Cancer Biomarkers

21/08/2014

When tackling any disease, the first step is to learn what signals its presence and what else these signs can mean. In discussing cancer, these signs are referred to as cancer biomarkers. Some organisations define a biomarker as a molecule that the cancerous tumor has secreted into the body, a...

Omixon Launches Holotype HLA™ for NGS-based HLA Genotyping

18/07/2014

Omixon announces the launch of Omixon Holotype HLA™ – a combination Assay and Software product that leverages the power of Next Generation Sequencing (NGS), for use on the Illumina® MiSeq sequencing platform. The assay and software have been optimized through cohesive collaboration with the Monos lab at The Children’s Hospital...

Omixon Celebrates a Successful EFI 2014

03/07/2014

Omixon took a team of 8 to the 28th EFI (European Histocompatibility and Immunogenetics) Conference, held in Stockholm. Omixon’s “A Team” of defenders (science nerds), midfielders (marketing bods) and strikers (sales weenies) were superbly captained by the indefatigable Craig Funnell (Director of Sales and Marketing), and brought super-sub Attila Berces...

Omixon Target Release Notes 1.9.1

01/07/2014

We are happy to let you know that a new version of Omixon Target is now available, including updated features and further improvements. Feel free to download the new version using the plugin on our website. When installing, select the ‘upgrade’ option to renew an existing installation. If you have the...

NGS-Based HLA Genotyping: Omixon and CHOP Collaborate

04/06/2014

Omixon is very proud to announce an exclusive licensing agreement with The Children’s Hospital of Philadelphia (CHOP) to commercialize a new Next Generation Sequencing (NGS) HLA genotyping assay, for use on the Illumina® MiSeq sequencing platform. The Illumina-specific HLA genotyping protocol was developed by Professor Dimitri Monos, Director of the...